FDA Approves DICLOFENAC SODIUM — BluePoint Laboratories

On January 27, 2020, BluePoint Laboratories received FDA approval for its ANDA No. 210986 to manufacture generic diclofenac sodium topical gel, 1%, directly challenging the domination of nonsteroidal anti-inflammatory drugs in the musculoskeletal pain relief market. This approval intensifies competition for (brand name reference if known) and intensifies generic pricing pressure on the local pain relief segment.